The research demonstrates its role in promoting lung adenocarcinoma development both in vitro and in vivo, suggesting that a TMEM176B inhibitor or neutralising antibody could be investigated for targeted therapy. The gene discussed is TMEM176B; the disease is lung adenocarcinoma.